News

The primary objective for this randomized placebo-controlled, Phase 2 study is to evaluate the efficacy and safety of the immuno-oncology-based combination compared to gemcitabine/ABRAXANE alone. Patients will also

 The complete response letter indicates additional clinical data are needed to further evaluate the safety of sirukumab in the treatment of moderately to severely active RA. "We are

The new company has been launched with a $103m Series A financing. Initially, SpringWorks will work on potential programs for four rare diseases – desmoid tumor, neurofibromatosis, hereditary xerocytosis

The new JV firm will focus on the use of nanolipogel (NLG) technology, which was developed by researchers from Yale University. The technology will enable to encapsulate different

Landos, founded by serial entrepreneur and innovator Dr. Josep Bassaganya-Riera, is advancing a robust pharmaceutical pipeline for autoimmune diseases toward commercialization and will partner operational efforts with Xontogeny,

In conjunction with this achievement, Eleven is ending its large-scale manufacturing activities and redirecting resources toward completing its Phase 3 trial and preparing for discussions with the U.S.

The two companies have entered into a clinical research collaboration in this regard to assess the therapeutic regimen in NSCLC and potentially other advanced solid tumors in the

Non-inferiority versus daily growth hormone was not demonstrated in the intent to treat (ITT) population for the primary efficacy variable, height velocity (HV) at 12 months. The 12-month

Bavencio, which is intended to be delivered intravenously, is a human antibody designed to inhibit the programmed death ligand-1 (PD-L1) protein. It has been developed to potentially engage